Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Invesco Small Cap Value Fund's investment thesis on Charles River Laboratories International, Inc. ($CRL) — Q4 2025 | Buyside Digest

All Pitches

View Letter Analysis

$CRLNYSECharles River Laboratories International, Inc.

BULL

Invesco Small Cap Value Fund—CRL

Fund Letter

Q4 2025

Published December 31, 2025

View Fund Profile

$295.01USD

+2.3% vs last month

$202.42Pitched

+45.7% since pitch

Market CapN/A

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

In Q4 2025, the Invesco Small Cap Value Fund outperformed its Russell 2000 Value Index benchmark, with stock selection in Information Technology serving as the primary performance driver, offsetting relative detractors in health care and financials. Portfolio managers Jonathan...

— Jonathan Edwards, Jonathan Mueller

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $CRL, and what else Invesco Small Cap Value Fund is buying.

Other pitches on $CRL

Other investors who've written on Charles River Laboratories International, Inc.

Madison Dividend Income FundBULL

Pitched Apr 18, 2026

Our investments in drug development companies like Charles River Labs (CRL) and Medpace Holdings (MEDP) pulled back, driven by AI disruption fears.

View all $CRL pitches →